Related Experiment Videos
Rationale for treatment of silent myocardial ischemia: focus on nifedipine
1Cardiology Section, New England Deaconess Hospital, Boston, MA 02215.
Insights
Most silent ischemic episodes in coronary artery disease patients occur without chest pain. This suggests treatment should focus on improving blood flow and oxygen supply, not just symptom relief.
Area of Science:
- Cardiology
- Ischemic Heart Disease
Background:
- A significant portion of ischemic episodes in ambulatory patients with coronary artery disease (CAD) occur without angina.
- This challenges traditional treatment approaches focused on symptomatic relief.
Purpose of the Study:
- To explore the implications of silent ischemia on medical management strategies for CAD patients.
- To review the use of nifedipine in treating silent ischemia.
- To re-evaluate therapeutic endpoints for CAD, considering silent ischemia.
Main Methods:
- Analysis of data from ambulatory Holter monitoring of the ST segment in CAD patients.
- Review of existing literature on nifedipine and silent ischemia treatment.
- Discussion of potential impacts on current treatment paradigms.
Main Results:
- Ambulatory ischemia is likely caused by increased myocardial oxygen demand and reduced coronary perfusion.
- Patients experiencing silent ischemia may have a poorer prognosis compared to those without.
- Current drug assessments may need re-evaluation if targeting ischemia abolition.
Conclusions:
- The prevalence of silent ischemia necessitates a shift in therapeutic goals for CAD.
- Treatment strategies should consider addressing underlying ischemia, not solely angina.
- Further research into drugs effective for silent ischemia is warranted.
Abstract:
The realization that the majority of ischemic episodes in ambulatory patients with coronary artery disease are not associated with angina has raised important questions regarding the medical management of such individuals. Data from studies utilizing ambulatory Holter monitoring of the ST segment suggest that ischemia is likely to be due to a combination of a modest rise in myocardial oxygen demand and a concomitant decrease in coronary perfusion. Patients with ambulatory ischemia may have a poorer survival than those without ischemia during daily activities. This paper will address the potential impact these new findings could have on treatment. A growing body of knowledge regarding the use of nifedipine for silent ischemia will be examined. Enthusiasm to make abolition of ischemia an end point of therapy in patients with coronary artery disease will necessitate a reexamination of drugs that have been assessed largely on their ability to provide symptomatic relief.